Literature DB >> 23037633

Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.

Koiti Inokuchi, Hiroki Yamaguchi, Hayato Tamai, Kazuo Dan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23037633     DOI： 10.3960/jslrt.52.145

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN： 1346-4280


× No keyword cloud information.
  3 in total

1.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

2.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

3.  Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.

Authors:  Weiyi Xu; Baode Chen; Xiangmin Tong
Journal:  Int J Hematol       Date:  2013-11-30       Impact factor: 2.490
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.